LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT03750513
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Anaplastic Ependymoma
  • Ependymoma

Eligibility Criteria

Sex
ALL
Age
N/A - 22 Years
Healthy Volunteers
Not accepted

Interventions

  • Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy — RADIATION
    Given LET optimized IMPT
  • Quality-of-Life Assessment — OTHER
    Ancillary studies
  • Questionnaire Administration — OTHER
    Ancillary studies

Study Details

This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.

Key Dates

Start date
Apr 1, 2019
Status verified
May 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
48 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (LET optimized IMPT)
    Patients receive LET optimized IMPT for up to 6 weeks.

Primary Outcome Measure

Incidence of adverse events [ Time Frame: Up to 6 months post treatment ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Massachusetts General Hospital Cancer CenterBostonMassachusetts02114
Kaden L Mitra Litzinger
[email protected]
Torunn Yock (PRINCIPAL_INVESTIGATOR)
M D Anderson Cancer CenterHoustonTexas77030
David R. Grosshans
713-563-2300
David R. Grosshans (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital Cancer Center· Boston, MAM D Anderson Cancer Center· Houston, TX

Related Studies